Purple Biotech (PPBT) said Tuesday it is advancing its drug candidate NT219 into a phase 2 clinical trial aimed at overcoming tumor resistance in therapies for recurring metastatic squamous cell cancer of the head and neck.
The study will evaluate the safety and efficacy of NT219 in combination with standard therapies like pembrolizumab and cetuximab, focusing on overcoming the resistance mechanisms tumors develop against such treatments, the company said.
Purple Biotech's shares were up over 10% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.